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subsequently underwent a cold-induced  [18F]FDG PET-
CT scan to assess BAT volume and activity. In addition, 
we included three replication cohorts consisting of in total 
thirty-seven healthy lean men that were similar with respect 
to age and BMI compared to the discovery cohort.
Results After correction for multiple testing, fasting con-
centrations of lysophosphatidylcholine-acyl (LysoPC-acyl) 
C16:1, LysoPC-acyl C16:0 and phosphatidylcholine-diacyl 
C32:1 showed strong positive correlations with BAT vol-
ume (β= 116 (85–148) mL,  R2 = 0.81, p = 4.6 × 10−7; β = 79 
(93–119) mL,  R2 = 0.57, p = 5.9 × 10−4 and β= 91 (40–141) 
mL,  R2 = 0.52, p = 1.0 × 10−3, respectively) as well as 
with BAT activity (β= 0.20 (0.11–0.29) g/mL,  R2 = 0.59, 
p = 1.9 × 10−4; β = 0.15 (0.06–0.23) g/mL,  R2 = 0.47, 
p = 2.0 × 10−3 and β= 0.13 (0.01–0.25) g/mL,  R2 = 0.28, 
p = 0.04, respectively). When tested in three independent 
replication cohorts (total n = 37), the association remained 
significant between LysoPC-acyl C16:0 and BAT activity 
in a pooled analysis (β= 0.15 (0.07–0.23) g/mL,  R2 = 0.08, 
p = 4.2 × 10−4).
Conclusions LysoPC-acyl C16:0 is associated with BAT 
activity in men. Since BAT is regarded as a promising tool 
Abstract 
Introduction Brown adipose tissue (BAT) recently 
emerged as a potential therapeutic target in the treatment 
of obesity and associated disorders due to its fat-burning 
capacity. The current gold standard in assessing BAT activ-
ity is  [18F]FDG PET-CT scan, which has severe limitations 
including radiation exposure, being expensive, and being 
labor-intensive. Therefore, indirect markers are needed of 
human BAT activity and volume.
Objective We aimed to identify metabolites in serum that 
are associated with BAT volume and activity in men.
Methods We assessed 163 metabolites in fasted serum 
of a cohort of twenty-two healthy lean men (age 24.1 
(21.7–26.6) years, BMI 22.1 (20.5–23.4) kg/m2) who 
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in the battle against obesity and related disorders, the iden-
tification of such a noninvasive marker is highly relevant.
Keywords [18F]FDG PET-CT scan · Brown adipose 
tissue · LysoPC-acyl C16:0 · Metabolomics
Abbreviations
ATP  Adenosine 5’ triphosphate
BAT  Brown adipose tissue
BMI  Body mass index
FDG  Fluorodeoxyglucose
HDL  High density lipoprotein
LCAT  Lecithin:cholesterol acyltransferase
LPL  Lipoprotein lipase
LysoPC  Lysophosphatidylcholine
OGTT  Oral glucose tolerance test
PC  Phosphatidylcholine
PET-CT  Positron emission tomography-computed 
tomography
T2DM  Type 2 diabetes mellitus
UCP-1  Uncoupling protein-1
WAT  White adipose tissue
1 Introduction
In humans, at least two types of adipose tissue are present, 
white adipose tissue (WAT) and beige or brown adipose tis-
sue (BAT). While the main function of WAT is the storage 
of fatty acids as triglycerides, BAT mainly oxidizes triglyc-
eride-derived fatty acids to generate heat in response to var-
ious physiological stimuli including cold exposure (Cannon 
and Nedergaard 2004). Brown adipocytes contain a wealth 
of mitochondria containing uncoupling protein 1 (UCP-1) 
that uncouples respiration from adenosine 5′ triphosphate 
(ATP) synthesis by allowing leakage of protons over the 
mitochondrial inner membrane, leading to heat production 
(Cannon and Nedergaard 2004).
Interestingly, recent studies have shown that activation 
of BAT by means of cold or capsinoids recruits BAT in 
relation to an increase in whole-body energy expenditure 
and reduces fat mass in healthy individuals (van der Lans 
et al. 2013; Yoneshiro et al. 2012, 2013). Moreover, repeti-
tive cold exposure improved glucose metabolism in patients 
with type 2 diabetes (Hanssen et al. 2015). Thus, albeit that 
the precise long term contribution of BAT to human energy 
expenditure remains to be determined, stimulation of BAT 
activity or ‘recruitment’ of BAT is currently considered a 
potential preventive and therapeutic target in the combat 
against obesity and related diseases, such as dyslipidemia 
(Hoeke et al. 2016) and type 2 diabetes mellitus (T2DM).
The current ‘gold standard’ for determination of BAT 
volume and BAT activity in humans is cold-induced  [18F]
fluorodeoxyglucose  ([18F]FDG) positron emission tomog-
raphy-computed tomography (PET-CT) (van der Lans 
et al. 2014). With this method, individuals are cooled down 
towards their shivering temperature, then stably cooled for 
1 h at a temperature just above their shivering temperature 
to ensure maximum non-shivering thermogenesis, followed 
by infusion of  [18F]FDG. After another hour of stable cool-
ing, a PET-CT scan is performed (van Marken Lichtenbelt 
et al. 2009). Uptake of  [18F]FDG by activated BAT regions 
on the PET-CT scan can be quantified, resulting in meas-
ures for BAT volume as well as for BAT activity.
The use of  [18F]FDG PET-CT scans to assess BAT vol-
ume and activity is limited by their high costs and radiation 
burden. Therefore, measures of BAT volume and activity 
have yet to be performed in large population-based stud-
ies. Identification of novel, less invasive, labor-intensive 
or expensive, methods to assess BAT volume and activity 
is warranted. BAT is a metabolically highly active tissue, 
even at room temperature, and rapidly takes up glucose and 
triglyceride-derived fatty acids for combustion. As a conse-
quence, metabolites that are produced or consumed due to 
BAT activity may change in plasma and thus, BAT volume 
and/or activity may be predicted by means of metabolites in 
serum. Therefore, the aim of the current study was to iden-
tify metabolites in a non-cooled state that are associated 
with BAT volume and/or activity in men.
2  Methods
2.1  Study population discovery cohort
Our discovery cohort consisted of twenty-four healthy male 
Caucasian (n = 12) and South Asian (n = 12) participants 
from a study that was performed previously in the Alri-
jne hospital (Leiderdorp, the Netherlands) between March 
and June 2013 (Bakker et al. 2014). This study was pow-
ered on the identification of a difference in BAT volume, 
resulting in inclusion of twelve subjects per group. Subjects 
were lean (BMI < 25 kg/m2) and healthy males aged 18–30 
years that were enrolled via local advertisements. Sub-
jects underwent a medical screening including their medi-
cal history, a physical examination, blood chemistry tests, 
and an oral glucose tolerance test (OGTT) to exclude indi-
viduals with T2DM according to the American Diabetes 
Association (ADA) 2010 criteria. Other exclusion criteria 
were rigorous exercise, smoking, and recent body weight 
change. Data from two individuals were removed from the 
analyses due to virtually absent BAT volume (0–1 mL) as 
assessed by  [18F]FDG PET-CT, leaving twenty-two partici-
pants. The present study was approved by the Medical Ethi-
cal Committee of the Leiden University Medical Center 
and performed in accordance with the principles of the 
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revised Declaration of Helsinki. All volunteers gave written 
informed consent before participation.
2.2  Study population replication cohorts
To verify whether the associations were sufficiently robust, 
we included three replication cohorts consisting of in 
total forty-two healthy Caucasian men. These participants 
were derived from three studies performed at the Maas-
tricht University Medical Centre (Maastricht, the Neth-
erlands) between 2011 and 2014 (Vosselman et  al. 2012, 
2013, 2015). In study 1, (Vosselman et al. 2015), aimed at 
studying the effect of exercise on BAT volume and activ-
ity, twelve healthy lean endurance-trained and twelve lean 
sedentary male Caucasian men aged 18–35 years were 
included. Endurance-trained athletes were included in the 
trained group when they performed endurance exercise at 
least three times a week for the last 2 years, and had a max-
imal oxygen consumption  (VO2max) of >55 mL/min/kg. 
The sedentary males were included in the untrained group 
if they did not perform more than 1 h of exercise per week 
for the last 2 years and had a  VO2max of <45 mL/min/kg. 
General exclusion criteria were use of medication, smok-
ing, weight gain/loss of >3 kg in the last 6 months, hyper-
tension and (family history of) diabetes. The trained men 
were included in replication cohort 1 and the untrained men 
in replication cohort 2.
Replication cohort 3 consisted of subjects derived from 
two studies (Vosselman et  al. 2012, 2013) that had the 
same inclusion criteria and cooling protocol. These studies 
aimed at studying the effect of β-adrenergic stimulation on 
BAT (Vosselman et al. 2012) and the effect of a high-calo-
rie meal on BAT (Vosselman et al. 2013). In these studies, 
in total 19 healthy male Caucasian subjects aged between 
18 and 35 years were enrolled. All subjects were screened 
for medical history. Cardiovascular status was screened by 
means of an electrocardiogram and blood pressure meas-
urement. All subjects had normal blood glucose levels.
In the replication cohorts, data from five participants 
were removed due to absence of  [18F]FDG uptake in the 
BAT region, leaving thirty-seven participants in the repli-
cation set. For the pooled analyses, fifty-nine participants 
were included in the analyses.
All replication studies were approved by the medical 
ethical committee of the Maastricht University Medical 
Center and all subjects were treated according to the princi-
ples of the revised declaration of Helsinki.
2.3  Study set-up discovery cohort
Individuals were studied in the morning after a 10-h over-
night fast and after 24  h without exercise. Subsequently, 
they were exposed to a thermoneutral temperature (32 °C) 
for 60  min, after which a basal blood serum sample was 
taken in which metabolites were also measured (see 
below). To activate BAT, an individualized cooling proto-
col was applied. In short, subjects lay on a bed sandwiched 
between two water-perfused cooling mattresses (Blanketrol 
III, Cincinnati Sub-Zero Products, Cincinnati, OH, USA). 
Cooling started from 32 °C and temperature was gradu-
ally decreased until shivering occurred (after 50–60 min). 
Temperature was then raised by 3–4 °C and the cool-
ing period of 2 h was started (defined as  tcold = 0 min). If 
shivering occurred, the temperature was raised in steps of 
1 °C until shivering stopped. Shivering was detected visu-
ally or was reported by participants. After 1  h of cooling 
 (tcold=60  min), 2  MBq/kg  [18F]FDG was injected intrave-
nously and subjects were instructed to lay still in order to 
prevent artifact by muscle activity. At  tcold = 110  min, a 
cold-induced blood sample was taken in which metabolites 
were measured as well. After 2 h of cooling  (tcold=120 min) 
the PET-CT scan (Gemini TF PET-CT, Philips, The Neth-
erlands) was performed to assess BAT volume and activity. 
Imaging was performed in three dimensional mode, with 
emission scans of 3 min per bed position in the upper part 
of the body (first seven bed positions) and scans of 30 s per 
bed position in the body area below, as described previ-
ously (Bakker et al. 2014). We quantified BAT activity and 
detectable volume in the region of interest by autocontour-
ing the BAT areas with a set threshold (SUV) of 2.0 g/mL 
using Hermes software (Hermes Hybrid Viewer, Hermes 
Medical Solutions, Sweden).
2.4  Study set-up replication cohorts
In all replication cohorts, subjects were studied in the morn-
ing after an overnight fast and after 24 h without exercise. 
All experiments started with 1-h baseline measurements 
during thermoneutral conditions (24–25 °C), after which a 
basal blood serum sample was taken in which metabolites 
were also measured (see below). Subsequently, subjects 
were exposed to 2 h of mild cold exposure in which an indi-
vidualized protocol was used by means of air cooling using 
air-conditioning. In short, each subject was cooled down 
until shivering occurred (approximately after 20–60 min). 
After that, air temperature was slightly increased until 
shivering stopped. After 1  h of cold exposure the  [18F]
FDG tracer was injected intravenously (74 MBq in replica-
tion cohorts 1 and 2 and 50 MBq in replication cohort 3) 
and subjects were exposed to another hour of cold. Next, 
after 2  h of cooling, the PET-CT scan (Gemini TF PET-
CT, Philips, the Netherlands) was performed to assess BAT 
volume and activity. Imaging was performed with emis-
sion scans of 6 min per bed position in the upper part of 
the body (six to seven bed positions) only. In replication 
cohort 1 and 2, BAT activity and detectable volume were 
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quantified in the region of interest by autocontouring the 
BAT areas with a set threshold (SUV) of 1.5 g/mL (Vos-
selman et al. 2015). In replication cohort 3 a threshold of 
1.5  g/mL was used as well, and additionally the regions 
drawn were localized in fat tissues only as determined by 
CT scan (HU −10 to −180) (Vosselman et  al. 2012). For 
all analyses, PMOD software (PMOD Technologies) was 
used.
2.5  Targeted metabolomics
Metabolomic measurements were performed on serum 
samples taken under thermoneutral and cold conditions at 
the Genome Analysis Center at the Helmholtz Zentrum, 
Munich, Germany, using the Biocrates AbsoluteIDQ™ 
p150 kit (BIOCRATES Life Science AG, Innsbruck, Aus-
tria) and ESI-FIA-MS/MS measurements (Menni et  al. 
2013). The assay allows simultaneous quantification of 163 
small molecule metabolites within 10 µL serum. The assay 
includes free carnitine, 40 acylcarnitines, 14 amino acids 
(13 proteinogenic + ornithine), hexoses (of which approx. 
90–95% is glucose), 92 glycerophospholipids including 
15 lysophosphatidylcholines (LysoPCs) and 77 phosphati-
dylcholines (PCs), and 15 sphingolipids (Menni et  al. 
2013; Illig et  al. 2010). Quantification of the metabolites 
was achieved by reference to appropriate internal stand-
ards. The assay has been previously described (Menni et al. 
2013; Illig et al. 2010).
2.6  Statistical analyses
First, all metabolites were Z-score transformed (i.e. cohort 
and ethnic-specific Z-scores) to make effect estimates 
between metabolites comparable. For the discovery cohort, 
multivariate linear regression analyses were used in both 
ethnicities separately to examine the associations between 
metabolites and BAT volume/activity, adjusting for age and 
body mass index. Pooled analyses for both ethnicities were 
performed by additionally adjusting the model for ethnicity. 
A p-value of 1.5 × 10−4 (= 0.05/(163 × 2) (163 metabolites 
tested against BAT volume and BAT activity)) was consid-
ered statistically significant.
For replication, we selected the one metabolite that 
reached the Bonferroni level of statistical significance and 
the two next ranked metabolites that were highly correlated 
to the top metabolite. Again, multivariate linear regression 
analyses were used to examine the associations between 
metabolites and BAT volume/activity, adjusting for age 
and body mass index. Pooled analysis for the replication 
was also achieved by additionally adjusting the model for 
the study set. For the replication, a p-value of 8.3 × 10−3 
(= 0.05/(3 × 2) (3 metabolites tested against BAT volume 
and BAT activity)) was considered to be statistically signif-
icant. Finally, we performed pooled analyses for these three 
metabolites from the five sub-studies (n = 59 participants). 
To this end, multivariate linear regression analyses were 
used (adjusting for age, body mass index and study set) and 
the same p-value of 8.3 × 10−3 was considered statistically 
significant. To compare levels of metabolites at thermon-
eutral temperature and after cold exposure in the discovery 
cohort, paired T-tests were used. All statistical analyses 
were performed in Stata 12.1 (StataCorp, Texas, USA) and 
the SPSS 20 (SPSS Inc, Chicago, IL, USA).
3  Results
3.1  Participant characteristics
The characteristics of the discovery cohort are shown 
in Table 1. All participants were male and mean age was 
24.1 years (range 21.7–26.6), while mean body mass index 
(BMI) was 22.1 kg/m2 (range 20.5–23.4). Mean BAT vol-
ume was 230 mL (range 158–299) and mean BAT activity 
Table 1  Participant characteristics of the discovery and replication studies








Vosselman et al. 2012, 2013
Age (years) 24.1 (21.7–26.6) 25.7 (22.0–32.0) 22.8 (19.0–24.5) 22.8 (21.0–24.0)
N (% males) 22 (100%) 11 (100%) 10 (100%) 16 (100%)
Body mass index (kg/m2) 22.1 (20.5–23.4) 21.2 (19.5–22.5) 22.1 (21.3–23.4) 22.1 (20.7–23.3)
Ethnicity (n of participants)
White Caucasian (%) 10 (46%) 11 (100%) 10 (100%) 16 (100%)
South Asian (%) 12 (54%) 0 (0%) 0 (0%) 0 (0%)
Brown adipose tissue volume (mL) 230 (158–299) 288 (164–480) 802 (551–1010)* 480 (167–766)*
Brown adipose tissue activity  (SUVmean, g/
mL)
4.17 (4.01–4.36) 2.12 (1.79–2.34) 2.52 (2.33–2.90) 2.35 (2.09–2.64)
LysoPC-acyl C16:0 is associated with brown adipose tissue activity in men 
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expressed as mean standardized uptake value  (SUVmean) 
4.17 g/mL (range 4.01–4.36). As compared to the discov-
ery cohort, the participants from the replication cohorts 
were similar with respect to gender, age and BMI. How-
ever, the participants from replication cohort 2 and 3 had 
higher detectable BAT volume (802 and 480 mL vs 230 
mL, respectively, both p < 0.05) and lower BAT activ-
ity (2.52 and 2.35  g/mL vs 4.17  g/mL, respectively, both 
p < 0.05) as compared to the discovery cohort.
3.2  The metabolites LysoPC-acyl C16:1, LysoPC-acyl 
C16:0 and PC-diacyl C32:1 highly correlate 
with BAT volume and activity in the discovery 
cohort
In search for metabolites in serum that are associated 
with BAT volume and activity, we measured 163 small 
molecule metabolites in fasting serum of the participants 
from our discovery cohort and correlated their concentra-
tions to BAT volume and activity using multivariate linear 
regression (Suppl Table SI). After correction for multiple 
testing, fasting concentrations of the metabolite LysoPC-
acyl C16:1 strongly positively associated with BAT vol-
ume (β= 116 (85–148) mL,  R2 = 0.81, p = 4.6 × 10− 7) 
(Fig.  1a) as well as BAT activity (β= 0.20 (0.11–0.29) g/
mL,  R2 = 0.59, p = 1.9 × 10− 4) (Fig.  1b). The estimated 
effect on BAT volume was 116 mL per standard devia-
tion increase (95% CI: 85, 148). These associations were 
found in both Caucasian individuals (p = 2.2 × 10− 3 for 
BAT volume and p = 3.0 × 10− 3 for BAT activity, respec-
tively) and South Asian individuals (p = 2.4 × 10− 3 for BAT 
volume and p = 0.06 for BAT activity, respectively). Also, 
its related metabolites LysoPC-acyl C16:0 (Fig.  1c) and 
PC-diacyl C32:1 (Fig. 1e) correlated positively with BAT 
volume (β= 79 (93–119) mL,  R2 = 0.57, p = 5.9 × 10− 4 and 
ß=91 (40–141) mL,  R2 = 0.52, p = 1.0 × 10− 3, respectively). 
Furthermore, LysoPC-acyl C16:0 (Fig.  1d) and PC-dia-
cyl C32:1 (Fig.  1f) correlated with BAT activity (β= 0.15 
(0.06–0.23) g/mL,  R2 = 0.47, p = 2.0 × 10− 3 and β= 0.13 
(0.01–0.25) g/mL,  R2 = 0.28, p = 0.04, respectively).
3.3  Cold exposure tends to increase serum levels 
of LysoPC-acyl C16:1 and LysoPC-acyl C16:0 
and increases LysoPC-diacyl C32:1 in the discovery 
cohort
To assess whether BAT activation directly influences levels 
of the three metabolites, we measured their levels in serum 
of our participants also after 2 h of stable cooling. Indeed, 
cooling tended to slightly increase levels of LysoPC-acyl 
C16:1 (+5%, p = 0.07, Fig.  2a) and LysoPC-acyl C16:0 
(+4%, p = 0.08, Fig. 2b), albeit that the increase was small. 
Moreover, cold exposure slightly increased PC-diacyl 
C32:1 levels (+9%, p = 0.007, Fig. 2c).
3.4  LysoPC-acyl C16:0 correlates with BAT activity 
in the replication cohorts
We next studied whether these three metabolites were 
sufficiently robust by performing a replication study in 
cohorts from a different academic center. Albeit that we 
could not reproduce the correlation between LysoPC-
acyl C16:1 and LysoPC-diacyl C32:1 and BAT volume 
and activity (Fig.  3), the effect estimates for LysoPC-
acyl C16:0 were all in the same direction (positive) as 
the discovery set (Table 2). In the replication, the pooled 
analysis for the correlation between LysoPC-acyl C16:0 
and BAT activity was nominally significant (p < 0.05), 
but fell slightly short of reaching statistical significance 
after Bonferroni correction (p = 0.01) (Table 2; Fig. 3d). 
However, when we assessed with the pooled association 
Fig. 1  Scatter plot of the associations between lysophosphatidyl-
choline-acyl C16:1 (lysoPC-acyl C16:1) with brown adipose tissue 
(BAT) volume (a) and b BAT activity  (SUVmean), between lysophos-
phatidylcholine-acyl C16:0 (lysoPC-acyl C16:0) with BAT volume 
(c) and BAT activity (d) and between phosphatidylcholine-diacyl 
C32:1 (PC-diacyl C32:1) with BAT volume (e) and BAT activity (f) 
in the discovery cohort (n = 22)
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of BAT volume and activity in all 59 participants (as 
shown in Table  2), LysoPC-acyl C16:0 was signifi-
cantly correlated with BAT activity (β= 0.15,  R2 = 0.08, 
p = 4.2 × 10−4) and the estimated effect on BAT activity 
was 0.15 per standard deviation increase (95% CI: 0.07, 
0.23).
4  Discussion
In the search for metabolites in serum associated with 
BAT, we found that BAT volume and activity highly cor-
related with LysoPC-acyl C16:1 (p = 4.6 × 10−7 and 
p = 1.0 × 10−6), LysoPC-acyl C16:0 (p = 5.9 × 10−4 and 
p = 8.2 × 10−4) and PC-diacyl C32:1 (p = 1.5 × 10−3 and 
p = 1.3 × 10−3) in a cohort of young lean men, irrespective 
of ethnicity. Furthermore, BAT activation by means of cold 
exposure increased LysoPC-diacyl C32:1 and tended to 
increase serum levels of LysoPC-acyl C16:1 and LysoPC-
acyl C16:0. Interestingly, the positive correlation between 
LysoPC-acyl C16:0 and BAT activity remained after pool-
ing of four study cohorts (p = 4.2 × 10−4), suggesting that 
LysoPC-acyl C16:0 may potentially be a marker that pre-
dicts BAT activity in adult men.
To the best of our knowledge, this is the first study 
investigating the correlation between metabolites in a 
non-cooled state and BAT volume and activity in human 
adults. Since BAT is regarded a promising tool in the bat-
tle against obesity and related disorders and noninvasive 
tools to estimate its volume and activity are not available, 
the identification of such a serum metabolite is highly rel-
evant. This can add in understanding the physiological role 
of human BAT and, furthermore, can be used in large pop-
ulation-based studies to study the effect of pharmacologi-
cal activation of human BAT without the need for invasive 
measurements.
It is interesting to speculate on the mechanism by which 
LysoPC-acyl C16:0 levels may be linked with BAT. BAT 
is a metabolically active organ that efficiently internalizes 
fatty acids from lipoproteins (Bartelt et  al. 2011), mostly 
derived from lipoprotein lipase (LPL)-mediated lipoly-
sis of triglycerides (Khedoe et  al. 2015). LPL-mediated 
Fig. 2  Effect of cold exposure (COLD) as compared to thermo-
neutrality (TN) on serum levels of lysophosphatidylcholine-acyl 
C16:1 (lysoPC-acyl C16:1) (a), lysophosphatidylcholine-acyl C16:0 
(lysoPC-acyl C16:0) (b) and phosphatidylcholine-diacyl C32:1 (PC-
diacyl C32:1) (c). Data are expressed as mean ± SEM and data were 
calculated by paired T-tests
Fig. 3  Scatter plot of the associations between lysophosphatidyl-
choline-acyl C16:1 (lysoPC-acyl C16:1) with brown adipose tis-
sue (BAT) volume (a) and BAT activity  (SUVmean) (b), between 
lysophosphatidylcholine-acyl C16:0 (lysoPC-cyl C16:0) with BAT 
volume (c) and BAT activity (d) and between phosphatidylcholine-
diacyl C32:1 (PC-diacyl C32:1) with BAT volume (e) and BAT activ-
ity (f) in the pooled replication cohorts (n = 37)
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processing of lipoproteins results in the generation of phos-
pholipid-rich surface remnants that will intercalate into the 
high density lipoprotein (HDL) pool and accept choles-
terol from peripheral tissues (Magill et  al. 1982). Indeed, 
we recently showed that BAT activation strongly increases 
reverse cholesterol transport in mice (Bartelt et  al. 2017), 
and that cold-induced BAT activation enhances the concen-
tration of specifically small HDL particles and cholesterol 
levels within these small HDL particles in men (G Hoeke 
and K Nahon, submitted). The efflux of cholesterol is prob-
ably coupled to rapid lecithin:cholesterol acyltransferase 
(LCAT)-mediated esterification of cholesterol with a fatty 
acid that is liberated from PC resulting in the generation 
of LysoPC (Eisenberg 1983; Glomset 1968; Magill et  al. 
1982). Of note, we also recently showed that 2  h of cold 
exposure increases LysoPC-acyl C16:0 in the HDL pool of 
lean men, but not obese men (Bartelt et al. 2017). Together 
with the finding that cold exposure tended to increase 
serum levels of LysoPC-acyl C16:1 and LysoPC-acyl 
C16:0 this suggests that LysoPCs are generated as a con-
sequence of BAT activity, albeit that we cannot exclude a 
contribution from other organs. For instance, white adipose 
tissue mobilization of fatty acids may, after processing, 
indirectly affect serum levels of LysoPC-acyl C16:1 and 
LysoPC-acyl C16:0. The fact that the increases in LysoPC-
acyl C16:1 and LysoPC-acyl C16:0 did not reach statistical 
significance may be related to the relative short duration of 
cold exposure.
After pooling of four study cohorts only the corre-
lation between LysoPC-acyl C16:0 and BAT activity 
remained significant. This may, at least in part, be due to 
the fact that the studies of the discovery cohort and repli-
cation cohorts were conducted in different medical cent-
ers. While in the discovery cohort water cooling was used 
to activate BAT, in the replication cohorts air cooling 
was used and this may have led to a submaximal activa-
tion of BAT. Although the amount of injected  [18F]FDG 
was lower in the replication cohorts, it is unlikely that 
this accounts for the lower measured  SUVmean since this 
was compensated by an increase in scanning time per bed 
position in the replication cohorts compared to the dis-
covery cohort (6 vs 3 min). Furthermore, the SUV thresh-
old set for definition of BAT activity was lower (1.5 vs 
2.0 g/mL) in the replication cohort, thus generally result-
ing in higher reported BAT volume. Indeed, reported 
BAT volume was markedly higher in replication cohorts 
Table 2  Associations between LysoPC-acyl C16:1, LysoPC-acyl C16:0, and PC-diacyl 32:1 and brown adipose tissue (BAT) volume and BAT 
activity
Values represent effect estimates (mL for volume, g/mLfor activity expressed as  SUVmean) per standard deviation change in metabolite concen-
tration. Model is adjusted for age and body mass index. In the pooled analyses, model is additionally adjusted for sub-study
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2 and 3 as compared to the discovery cohort. In replica-
tion cohort 3, for determination of BAT volume CT HU 
between −10 and −180 were used. This increases the 
selectivity for fat tissue but may result in underestimation 
of BAT volume (Van der Lans et al. 2014). However, as 
compared to the discovery cohort, BAT volume was actu-
ally increased in replication cohort 3, which is likely due 
to the lower BAT detection limit (e.g. 1.5  g/mL). Also, 
software used to analyze BAT volume and activity dif-
fered between discovery cohort and replication cohorts. 
This may have affected the quantitative measures of BAT 
activity (especially  SUVmean) and volume. Furthermore, 
one of the replication cohorts included athletes. This may 
have increased heterogeneity in the replication cohort due 
to the fact that they had a slightly different body composi-
tion (lower fat mass) and lower BAT activity compared to 
the sedentary cohort (Vosselman et al. 2015). All of the 
above-mentioned methodological issues may have made 
our replication less robust. Still, despite these methodo-
logical issues, the pooled analyses showed that the cor-
relation between LysoPC-acyl C16:0 and BAT activity 
remained significant. However, we do suggest for future 
studies and comparative reasons to keep thresholds and 
other settings equal between studies (Chen et  al. 2016). 
Another potential limitation of our study is that we only 
included lean male participants in our study and, there-
fore, results may not apply to women nor obese subjects. 
Future studies should assess whether LysoPC-acyl C16:0 
could also serve as a potential marker of BAT activity in 
these groups.
For our analyses, we excluded two participants with 
virtually absent BAT as assessed by PET-CT scan using 
the glucose tracer  [18F]FDG. Of note, one of these par-
ticipants had a very high  [18F]FDG uptake in intercostal 
muscles (Bakker et al. 2014). Also, low  [18F]FDG uptake 
does not exclude the presence of BAT and other biologi-
cal mechanisms such as insulin resistance may underlie 
the low glucose uptake in these subjects. In fact, a recent 
study from Blondin et  al. (Blondin et  al. 2015) showed 
that glucose uptake by BAT does not correlate with 
uptake of  [18F]FTHA (a measure of nonesterified fatty 
acid uptake) nor with  [11C]acetate (a measure of the oxi-
dative capacity of the tissue). Still, re-analysis of the cor-
relation between BAT volume and LysoPC-acyl C16:1 in 
discovery population showed that the correlation was still 
highly significant (p = 1.2 × 10−5) when the BAT nega-
tive subject is included. Furthermore, in our study, we 
used a stringent Bonferroni correction, which assumes 
that all metabolites are independent from each other. 
However, many of the metabolites are in fact highly cor-
related to each other and, therefore, a Bonferroni correc-
tion is overly conservative. Finally, we found no evidence 
for heterogeneity (p = 0.42) for the association between 
LysoPC-acyl C16:0 and BAT activity, further underlining 
the robustness of our finding.
In conclusion, in the current study we show a robust 
positive correlation between serum LysoPC-acyl C16:0 
levels and BAT activity. LysoPC-acyl C16:0 could poten-
tially serve as a marker to predict BAT activity in a non-
invasive way. Further larger studies, also encompassing a 
wider range of metabolites, are required to find additional 
predictors for BAT volume and activity.
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